The pineal regulation of the immune system: 40 years since the discovery

Acta Microbiologica et Immunologica Hungarica

Volumn 60, Issue 2, 2013, Pages 77-91

  Csaba, György ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

cancer; immune cells; local regulation; melatonin; pineal; thymus

Indexed keywords

MELATONIN; MELATONIN RECEPTOR; PINEAL BODY HORMONE;

HORMONE TRANSPORT; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; NEOPLASM; NONHUMAN; PINEAL BODY; REVIEW; THYMUS;

EID: 84880201357     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.60.2013.2.1     Document Type: Review

References (100)

1. McIntire KR, Sell S, Miller JF: Pathogenesis of the postneonatal thymectomy wasting syndrome. Nature 204, 151-155 (1964).
2. Lerner AB, Case JD, Takahashi Y: Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem 235, 1992-1997 (1960).
3. Csaba G, Kiss J, Bodoky M: Uptake of radioactive iodine by the thyroid after pinealectomy. Acta Biol Acad Sci Hung 19, 35-41 (1968).
4. Kiss J, Bánhegyi D, Csaba G: Endocrine regulation of the blood calcium level II. Relationship between the pineal body and the parathyroid glands. Acta Med Acad Sci Hung 26, 363-370 (1969).
5. Csaba G, Baráth P: Are Langerhans islets influenced by the pineal body? Experientia 27, 962 (1971).
6. Csaba G, Nagy SU: The regulatory role of the pineal gland on the thyroid gland, adrenal medulla, and islets of Langerhans. Acta Biol Med Ger 31, 617-619 (1973).
7. Csaba G, Bodoky M, Fischer J, Ács T: The effect of pinealectomy and thymectomy on the immune capacity of the rat. Experientia 22, 168-169 (1966).
8. Csaba G, Rados I, Wohlmuth E: Wasting disease and tetany following neonatal pinealectomy. Acta Med Acad Sci Hung 29, 231-240 (1973).
9. Baráth P, Csaba G: Histological changes in the lung, thymus and adrenal one and a half year after pinealectomy. Short communication. Acta Biol Acad Sci Hung 25, 123-126 (1974).
10. Csaba G, Baráth P: Morphological changes of thymus and the thyroid gland after postnatal extirpation of the pineal body. Endocrinol Exp 9, 59-57 (1975).
11. Rella W, Lapin V: Immunocompetence of pinealectomized and simultaneously pinealectomized and thymectomized rats. Oncology 33, 3-6 (1976).
12. Vermeulen M, Palermo M, Giordano M: Neonatal pinealectomy impairs murine antibody dependent cellular cytotoxicity. J Neuroimmunol 43, 97-101 (1993).
13. Maestroni GJ: The immunoneuroendocrine role of melatonin. J Pineal Res 14, 1-10 (1993).
14. Martin-Cacao A, Lopez-Gonzalez MA, Reiter RJ, Calvo JR, Guerrero JM: Binding of 2-[125I] melatonin by rat thymus membranes during postnatal development. Immunol Lett 36, 59-63 (1993).
15. Pertsov SS: Effect of melatonin on the thymus, adrenal glands and spleen in rats during acute stress. Bul Exp Biol Med 141, 292-295 (2006).
16. Öner H, Kus I, Öner J, Ögetürk M, Ozan E, Ayar A: Possible effects of melatonin in thymus gland after pinealectomy in rats. Neuroendocrinol Lett 25, 115-118 (2004).
17. Tian YM, Zhang GY, Dai YR: Melatonin rejuvenates degenerated thymus and redresses peripheral immune functions in aged mice. Immunol Lett 88, 101-104 (2003).
18. Hadden JW: Thymic endocrinology. Ann N Y Acad Sci 840, 352-358 (1998).
19. Naranjo MC, Guerrero JM, Rubio A, Lardone PJ, Carrillo-Vico A, Carrascosa-Salmoral MP, Jiménez-Jorge S, Arellano MV, Leal-Noval SR, Leal M, Lissen E, Molinero P: Melatonin biosynthesis in the thymus of humans and rats. Cell Mol Life Sci 64, 781-790 (2007).
20. Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernández- Montesinos R, Guerrero JM, Pozo D: The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs 7, 423-431 (2006).
21. Cardarelli NF: The role of thymus-pineal axis in an immune mechanism of aging. J Theor Biol 145, 397-405 (1990).
22. Markus RP, Ferreira ZS, Fernandes PA, Cecon E: The immune-pineal axis: A shuttle between endocrine and paracrine melatonin sources. Neuroimmunomodulation 14, 126-133 (2007).
23. Polyakova VO, Linkova NS, Kvetnoy IM, Khavinson VKH: Functional unity of the thymus and pineal gland and study of the mechanism of aging. Bull Exp Biol Med 151, 627-630 (2011).
24. Khavinson VKH, Morozov VG: Peptides of the pineal gland and thymus prolong human life. Neuro Endocrinol Lett 24, 233-240 (2003).
25. Hardeland R: Melatonin and 5-methoxytryptamine in non-metazoans. Reprod Nutr Dev 39, 399-408 (1999).
26. Hardeland R, Pandi-Perumal SR, Cardinali DP: Melatonin. Int J Biochem Cell Biol 38, 313-316 (2006).
27. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Poeggeler B, Hardeland R: Melatonin: Nature's most versatile biological signal? FEBS J 272, 2813-2838 (2006).
28. Csaba G: Presence in and effects of pineal indoleamines at very low level of phylogeny. Experientia 48, 627-634 (1993).
29. Kõhidai L, Vakkuri O, Keresztesi M, Leppaluoto J, Csaba G: Melatonin in the unicellular Tetrahymena pyriformis: effects of different lighting conditions. Cell Biochem Funct 20, 269-272 (2002).
30. Kõhidai L, Vakkuri O, Keresztesi M, Leppaluoto J, Csaba G: Induction of melatonin synthesis in Tetrahymena pyriformis by hormonal imprinting-a unicellular "factory" of the indoleamine. Cell Mol Biol 49, 521-524 (2003).
31. Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF: Evidence for a direct action of melatonin on the immune system. Biol Signals 3, 107-117 (1994).
32. Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR: Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 62, 282-287 (2010).
33. Dawoodi Z, Shah N, De Sous A: Melatonin agonists: A brief clinical review. Delhi Psych J 15, 268-273 (2012).
34. Carlberg C: The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: An unexpected relationship. J Pineal Res 18, 171-178 (1995).
35. Raffi-el-Idrisi M, Calvo JR, Harmouch A, Garcia-Maurino S, Guerrero JM: Specific binding of melatonin by purified cell nuclei from spleen and thymus of rat. J Neuroimmunol 86, 190-197 (1998).
36. Carrillo-Vico A, Garcia-Perganeda A, Naji L, Calvo JR, Romero MP, Guerrero JM: Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cell Mol Life Sci 60, 2272-2278 (2003).
37. Carrillo-Vico A, Garcia-Maurino S, Calvo JR, Guerrero JM: Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptors. FASEB J 17, 755-757 (2003).
38. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Maurino S, Reiter RJ, Guerrero JM: Evidence of melatonin synthesis by human lymphocytes and its physiological significance: Possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 18, 537-539 (2004).
39. Sanchez-Bárceló E, Martinez-Camps CM, Mediavilla MD, Gonzalez A, Alonso-Gonzalez C, Cos S: Melatonin and melatoninergic drugs as therapeutic agents: Ramelteon and agomelatine, the two most promising melatonin receptor agonists. Rec Pat Endocr Metab Imm Drug Disc 1, 142-151 (2007).
40. Couto-Moraes R, Palermo-Neto J, Markus RP: The immune-pineal axis: Stress as a modulator of pineal gland function. Ann N Y Acad Sci 1153, 193-202 (2009).
41. Srinivasan V, Zakaria R, Othman Z, Lauterbach EC, Acuna-Castroviejo D: Agomelatine in depressive disorders: Its novel mechanism of action. J Neuropsychiatry Clin Neurosci 24, 290-308 (2012).
42. Maestroni GJ, Conti A, Pierpaoli W: Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol 13, 19-30 (1986).
43. Fraschini F, Demartini G, Esposti D, Scaglione F: Melatonin involvement in immunity and cancer. Biol Signals 7, 61-72 (1998).
44. Radogna F, Diederich M, Ghibelli L: Melatonin: A pleiotropic molecule regulating inflammation. Biochem Pharmacol 80, 1844-1852 (2010).
45. Szczepanik M: Melatonin and its influence on immune system. J Physiol Pharmacol 58, Suppl 6, 115-124 (2007).
46. Cardinali DP, Esquifino AI, Srinivasan V, Pandi-Perumal SR: Melatonin and the immune system in aging. Neuroimmunomodulation 15, 272-278 (2008).
47. Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP: Therapeutic action of melatonin in cancer: Possible mechanisms. Integr Cancer Ther 7, 189-203 (2008).
48. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ: Immunomodulation by melatonin: Its significance for seasonally occurring diseases. Neuroimmunomodulation 15, 93-101 (2008).
49. Srinivasan V, Maestroni GJM, Cardinali DP, Esquifino Ai, Pandi-Perumal SR, Miller SC: Melatonin, immune function and aging. Immunity & Ageing 2, 17 (2005).
50. Gupta S, Haldar C: Physiological crosstalk between melatonin and glucocorticoid receptor modulates T-cell mediated immune responses in a wild tropical rodent, Funambulus pennanti. J Steroid Biochem Mol Biol 134, 23-36 (2013).
51. Walton JC, Weil ZM, Nelson RJ: Influence of photoperiod on hormones, behavior and immune function. Front Neuroendocrinol 32, 303-319 (2011).
52. Maestroni GJ: Therapeutic potential of melatonin in immunodeficiecy states, viral diseases and cancer. Adv Exp Med Biol 467, 217-226 (1999).
53. Maestroni GJ: The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 10, 467-476 (2001).
54. Santello FH, Frare EO, Caetani LC, Alonso Toldo MP, do Prado JC: Melatonin enhances pro-inflammatory cytokine levels and protects against Chagas disease. J Pineal Res 45, 79-85 (2008).
55. del Gobbo V, Libri V, Villani N, Calió R, Nisticó G: Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int J Immunopharmacol 11, 567-573 (1989).
56. Huai JP, Sun XC, Chen MJ, Jin Y, Ye XH, Wu JS, Huang ZM: Melatonin attenuates acute pancreatitis-associated lung injury in rats by modulating interleukin 22. World J Gastroenterol 18, 5122-5128 (2012).
57. Esposito E, Cuzzocrea S: Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8, 228-242 (2010).
58. Reiter RJ, Calvo JR, Karbownik M, Qi W, Tan DX: Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 917, 376-386 (2000).
59. Maestroni GJ: T-helper-2 lymphocytes as a peripheral target of melatonin. J Pineal Res 18, 84-89 (1995).
60. Guerrero JM, Reiter RJ: A brief survey of pineal gland-immune system interrelationship. Endocr Res 18, 91-113 (1992).
61. Cutando A, Silvestre FJ: Melatonin: Implications at the oral level. Bull Group Int Res Stomatol Odontol 38, 81-86 (1995).
62. Maestroni GJ: Is hematopoesis under the influence of neural and neuroendocrine mechanisms? Histol Histopathol 13, 271-274 (1998).
63. Rai S, Haldar C: Pineal control of immune status and hematological changes in blood and bone marrow of male squirrels (Fubambulus pennanti) during their reproductively active phase. Comp Biochem Physiol C 136, 319-328 (2003).
64. Zhou W, Wang PM, Tao L: Effect of melatonin on proliferation of neonatal cord blood mononuclear cells. World J Pediatr 5, 300-303 (2009).
65. Mazzoccoli G, Inglese M, De Cata A, Carughi S, Dagostino MP, Marzulli N, Damato M, Grilli M, Giuliani F, Greco A: Neuroendocrine-immune ineractions in healthy aging. Geriatr Gerontol Int 11, 98-106 (2011).
66. Akbulut KG, Gönül B, Akbulut H: The effects of melatonin on humoral immune responses of young and aged rats. Immunol Invest 30, 17-20 (2001).
67. Macchi MM, Bruce JN: Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 25, 177-195 (2004).
68. Maldonado MD, Férez-San-Gregorio MA, Reiter RJ: The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CBS Drug Discov 4, 61-69 (2009).
69. Blask DE: Melatonin, sleep disturbance and cancer risk. Sleep Med Rev 13, 257-264 (2000).
70. Reiter RJ: Melatonin: Clinical relevance. Best Pract Res Clin Endocrinol Metab 17, 273-285 (2003).
71. Bukowska A: Anticarcinogenic role of melatonin-potential mechanisms. Med Pr 62, 425-434 (2011).
72. Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ: The role of melatonin in immuno-enhancement: Potential application in cancer. Int J Exp Pathol 87, 81-87 (2006).
73. Vigoré L, Messina G, Brivio F, Fumagalli L, Rovelli F, Di Fede G, Lissoni P: Psychoneuroendocrine modulation of regulatory T. lymphocyte system: in vivo and in vitro effects of the pineal immunomodulating hormone melatonin. In Vivo 24, 797-799 (2010).
74. Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ: Anticancer neuroimmunomodulation by pineal hormones other than melatonin: Preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin. J Biol Regul Homeost Agents 1, 119-122 (1997).
75. Bubenik GA, Blask DE, Brown GM et al.: Prospects of the clinical utilization of melatonin. Biol Signals Recept 7, 195-219 (1998).
76. Lissoni P: Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci 917, 560-567 (2000).
77. Lissoni P, Rovelli F, Frassineti A, Fumagalli L, Malisheva O, Conti A, Maestroni G: Oncostatic activity of pineal neuroendocrine treatment with indoles melatonin and 5-methoxytryptamine in untreatable cancer patients progressing on melatonin alone. Nature Endocrinol Lett 21, 319-323 (2000).
78. Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F: Neuroimmunomodulation in medical oncology: Application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 28, 1377-1381 (2008).
79. Lissoni P, Rovelli F: Principles of psychoneuroendocrinoimmunotherapy of cancer. Immunotherapy 4, 77-86 (2012).
80. Bartsch C, Bartsch H: Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 467, 247-264 (1999).
81. Lissoni P, Rovelli F, Giani L, Fumagalli L, Manadala M: Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients. Nat Immun 16, 178-184 (1998).
82. Lissoni P, Giani L, Zerbini S, Trabattoni P, Rovelli F: Biotherapy with the immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. Nat Immun 16, 27-33 (1998).
83. Dziegiel P, Podhorska-Okolow M, Zabel M: Melatonin: Adjuvant therapy of malignant tumors. Med Sci Monit 14, RA64-RA70 (2008).
84. Carpentieri A, Diaz de Barboza G, Areco V, Peralta López M, Tolosa de Talamoni N: New perspectives in melatonin uses. Pharmacol Res 65, 437-444 (2012).
85. Park HJ, Kim HJ, Lee JY: Adrenocorticotropin hormone stimulates interleukin-18 expression in human HaCaT keratinocytes. J Invest Dermatol 127, 1210-1216 (2007)
86. Berczi I, Quintanar-Stefano A, Kovacs K: Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci 1153, 220-239 (2009).
87. Zaldivar V, Magri ML, Zárate S, Jaita G, Eijo G, Radl D, Ferraris J, Pisera D, Seilichovich A: Estradiol increases the expression of TNF-alpha and TBF receptor 1 in lactotropes. Neuroendocrinology 93, 106-113 (2011).
88. Oh SH, Park CO, Wu WH, Kim JY, Jin S, Byamba D, Bae BG, Noh S, Lim BJ, Noh JY, Lee KH: Corticotropin-releasing hormone downregulates IL-10 production by adaptive forhead box protein 3-negative regulatory T cells in patients with atopic dermatitis. J Allergy Clin Immunol 129, 151-159 (2012).
89. Csaba G: The immunoendocrine system: Hormones, receptors and endocrine function of immune cells. The packed transport theory. Adv Neuroimm Biol 1, 71-85 (2011).
90. Reiter RJ, Maestroni GJ: Melatonin in relation to the antioxidative defense and immune systems possible implications for cell and organ transplantation. J Mol Med 77, 36-39 (1999).
91. Reiter RJ: The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Min Rev Med Chem 13, 373-384 (2013)
92. Reiter RJ, Tan DX, Fuentes-Broto L: Melatonin: A multitasking molecule. Prog Brain Res 181, 127-151 (2010).
93. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ: Basic mechanism involved in the anti-cancer effects of melatonin. Curr Med Chem 17, 4462-4481 (2010).
94. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch Nostrom RS, Slominski AT: Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol 351, 152-166 (2012).
95. Reiter RJ: Cytoprotective properties of melatonin presumed with oxidative damages and aging. Nutrition 14, 691-696 (1998).
96. Csaba G: atHormonal regulation: Morphogenetic and adaptive systems. Biol Rev Camb Philos Soc 52, 295-303 (1977).
97. Erren TC, Reiter RJ: A generalized theory of carcinogenesis due to chronodisruption. Neuro Endocrinol Lett 29, 815-821 (2008).
98. Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, Brivio O, Esposti G: Melatonin as a new possible anti-inflammatory agent. J Biol Regul Homeost Agents 11, 157-159 (1997).
99. Lissoni P: Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-Methoxytryptamine as a new oncostatic pineal agent. Pathol Biol 55, 198-200 (2007).
100. Sánchez-Barceló EJ, Mediavilla MD, Tan DX, Reiter RJ: Clinical uses of melatonin: Evaluation of human trials. Curr Med Chem 17, 2070-2095 (2010).